Portal de Periódicos da CAPES

Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France

2010; Oxford University Press; Volume: 65; Issue: 12 Linguagem: Inglês

10.1093/jac/dkq380

1460-2091

Diane Descamps, Marie‐Laure Chaix, Brigitte Montès, Sophie Pakianather, C. Charpentier, Alexandre Storto, Francis Barin, Georges Dos Santos, Anne Krivine, Constance Delaugerre, Jacques Izopet, Anne‐Geneviève Marcelin, Anne Maillard, Laurence Morand‐Joubert, C. Pallier, Jean‐Christophe Plantier, Catherine Tamalet, Jacqueline Cottalorda, Delphine Desbois, Vincent Cálvez, Françoise Brun‐Vézinet, Bernard Masquelier, Dominique Costagliola, Chakib Alloui, Dominique Bettinger, Guerric Anies, Bernard Masquelier, Sophie Vallet, Cécile Henquell, Magali Bouvier‐Alias, G. DosSantos, Anne Signori-Schmück, Sylvie Ranger‐Rogez, Patrice André, J. C. Tardy, Mary‐Anne Trabaud, Catherine Tamalet, Brigitte Montès, Jacqueline Cottalorda, Diane Descamps, Françoise Brun‐Vézinet, Charlotte Charpentier, Marie‐Laure Chaix, Delphine Desbois, Slim Fourati, Anne‐Geneviève Marcelin, Vincent Cálvez, Philippe Flandre, Laurence Morand‐Joubert, Constance Delaugerre, Annick Ruffault, Anne Maillard, Jean‐Christophe Plantier, Thomas Bourlet, Hénia Saoudin, Jacques Izopet, Francis Barin,

HIV/AIDS Research and Interventions

To estimate the prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-1-infected patients in France. Resistance mutations were sought in samples from 530 newly diagnosed HIV-1-infected patients from October 2006 to March 2007. Protease and reverse transcriptase mutations were identified from the 2007 Stanford Resistance Surveillance list. Reverse transcriptase and protease resistance mutations were determined in 466 patients with duration of seropositivity <5 years. 42% of patients were infected with non-B subtype strains (CRF02 18.3%). The overall prevalence of viruses with protease or reverse transcriptase mutations was 10.6% (95% confidence interval 6.7–16.3). The prevalence of protease inhibitor, nucleoside reverse transcriptase inhibitor and non-nucleoside reverse transcriptase inhibitor resistance-associated mutations was 4.7%, 5.8% and 2.8%, respectively. Frequency of resistance was not different in patients infected with B (9.5%) and non-B (CRF02 7.8% and other 11.2%) subtypes. Baseline characteristics such as gender, age, transmission group, country of transmission, disease stage, CD4 counts and viral load were not associated with the prevalence of transmitted drug resistance. In France in 2006/2007, the prevalence of transmitted drug-resistant variants was 10.6%. Prevalence of transmitted drug resistance was comparable in B and non-B subtypes. Prevalence of non-B subtypes is still rising.